JP2020524496A - ジカウイルスタンパク質を発現する組換え麻疹ウイルス及びその適用 - Google Patents

ジカウイルスタンパク質を発現する組換え麻疹ウイルス及びその適用 Download PDF

Info

Publication number
JP2020524496A
JP2020524496A JP2019567572A JP2019567572A JP2020524496A JP 2020524496 A JP2020524496 A JP 2020524496A JP 2019567572 A JP2019567572 A JP 2019567572A JP 2019567572 A JP2019567572 A JP 2019567572A JP 2020524496 A JP2020524496 A JP 2020524496A
Authority
JP
Japan
Prior art keywords
zikv
protein
seq
sequence
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2019567572A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524496A5 (enExample
Inventor
フレデリック・タンギー
エティエンヌ・シモン−ロリエール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Pasteur
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Pasteur filed Critical Centre National de la Recherche Scientifique CNRS
Publication of JP2020524496A publication Critical patent/JP2020524496A/ja
Publication of JP2020524496A5 publication Critical patent/JP2020524496A5/ja
Priority to JP2023081004A priority Critical patent/JP2023107780A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18423—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
    • G01N2333/12—Mumps virus; Measles virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019567572A 2017-06-07 2018-06-06 ジカウイルスタンパク質を発現する組換え麻疹ウイルス及びその適用 Ceased JP2020524496A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023081004A JP2023107780A (ja) 2017-06-07 2023-05-16 ジカウイルスタンパク質を発現する組換え麻疹ウイルス及びその適用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305676.3 2017-06-07
EP17305676.3A EP3412307A1 (en) 2017-06-07 2017-06-07 Recombinant measles virus expressing zika virus proteins and their applications
PCT/EP2018/064943 WO2018224573A1 (en) 2017-06-07 2018-06-06 Recombinant measles virus expressing zika virus proteins and their applications

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023081004A Division JP2023107780A (ja) 2017-06-07 2023-05-16 ジカウイルスタンパク質を発現する組換え麻疹ウイルス及びその適用

Publications (2)

Publication Number Publication Date
JP2020524496A true JP2020524496A (ja) 2020-08-20
JP2020524496A5 JP2020524496A5 (enExample) 2021-07-26

Family

ID=59276634

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019567572A Ceased JP2020524496A (ja) 2017-06-07 2018-06-06 ジカウイルスタンパク質を発現する組換え麻疹ウイルス及びその適用
JP2023081004A Pending JP2023107780A (ja) 2017-06-07 2023-05-16 ジカウイルスタンパク質を発現する組換え麻疹ウイルス及びその適用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023081004A Pending JP2023107780A (ja) 2017-06-07 2023-05-16 ジカウイルスタンパク質を発現する組換え麻疹ウイルス及びその適用

Country Status (9)

Country Link
US (1) US11857616B2 (enExample)
EP (2) EP3412307A1 (enExample)
JP (2) JP2020524496A (enExample)
CN (1) CN110891600B (enExample)
AU (1) AU2018281889B2 (enExample)
BR (1) BR112019025310A2 (enExample)
CA (1) CA3064322A1 (enExample)
MX (1) MX2019014674A (enExample)
WO (1) WO2018224573A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023107780A (ja) * 2017-06-07 2023-08-03 アンスティテュ・パストゥール ジカウイルスタンパク質を発現する組換え麻疹ウイルス及びその適用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3031923A1 (en) * 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
EP3419660A4 (en) * 2016-02-25 2019-11-06 The Trustees Of The University Of Pennsylvania NOVEL VACCINES AGAINST ZIKA VIRUS
KR101966841B1 (ko) * 2018-12-12 2019-04-08 대한민국 지카바이러스 e 단백질 유래의 재조합 항원 및 이의 용도
BR112021020325A2 (pt) * 2019-04-10 2021-12-14 Univ Leuven Kath Vírus quimérico zika-encefalite japonesa
CN113999823B (zh) * 2021-12-30 2022-04-26 北京赛尔富森生物科技有限公司 D8基因型嵌合麻疹病毒减毒株和制备方法及用途
CN119072491A (zh) * 2022-02-22 2024-12-03 维罗生物公司 用于递送外源多核苷酸的核酸组合物及使用方法
AU2023362558A1 (en) * 2022-10-21 2025-05-08 Theravectys Polynucleotides and lentiviral vectors expressing non-structural antigens of a flavivirus selected from the group of denv, zikv and yfv, inducing protective cd8+ t-cell immunity in a host

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015532090A (ja) * 2012-09-27 2015-11-09 アンスティテュ・パストゥール チクングニアウイルスポリペプチドを発現する組換え麻疹ウイルスおよびその適用
WO2016199936A1 (ja) * 2015-06-12 2016-12-15 国立大学法人三重大学 ヒトパラインフルエンザ２型ウイルスベクター及びワクチン

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2330309T3 (es) 2002-06-20 2009-12-09 Institut Pasteur Adnc infeccioso de una cepa de vacuna aprobada de virus del sarampion. uso para composiciones inmunogenicas.
ES2423518T3 (es) 2006-12-22 2013-09-20 Institut Pasteur Células y metodología para generar virus de ARN de cadena de sentido negativo no segmentada
WO2016210127A1 (en) * 2015-06-25 2016-12-29 Technovax, Inc. Flavivirus and alphavirus virus-like particles (vlps)
EP3184119A1 (en) * 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
EP3412307A1 (en) * 2017-06-07 2018-12-12 Institut Pasteur Recombinant measles virus expressing zika virus proteins and their applications

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015532090A (ja) * 2012-09-27 2015-11-09 アンスティテュ・パストゥール チクングニアウイルスポリペプチドを発現する組換え麻疹ウイルスおよびその適用
WO2016199936A1 (ja) * 2015-06-12 2016-12-15 国立大学法人三重大学 ヒトパラインフルエンザ２型ウイルスベクター及びワクチン

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [ONLINE], NO. HQ234500.1, 2012.5.19, INTERNET, <URL:HTTPS://WWW.NCBI.NLM.NIH.GOV/NU, JPN6022027862, ISSN: 0004963762 *
DATABASE GENBANK [ONLINE], NO. KF383115.1, 2014.5.15, INTERNET, <URL:HTTPS://WWW.NCBI.NLM.NIH.GOV/NU, JPN6022027861, ISSN: 0004963761 *
DATABASE GENBANK [ONLINE], NO. KU365777.1, 2016.1.26, INTERNET, <URL:HTTPS://WWW.NCBI.NLM.NIH.GOV/NU, JPN6022027860, ISSN: 0004963763 *
ROLE OF ZIKV CHIM IN VACCINE EVALUATION, 2017.6.2, RETRIEVED FROM THE INTERNET, RETRIEVED ON 2017.10, JPN6022027864, ISSN: 0004963760 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023107780A (ja) * 2017-06-07 2023-08-03 アンスティテュ・パストゥール ジカウイルスタンパク質を発現する組換え麻疹ウイルス及びその適用

Also Published As

Publication number Publication date
CN110891600B (zh) 2024-04-02
AU2018281889A1 (en) 2019-12-19
EP3634482A1 (en) 2020-04-15
JP2023107780A (ja) 2023-08-03
US20200237893A1 (en) 2020-07-30
MX2019014674A (es) 2020-09-07
EP3412307A1 (en) 2018-12-12
WO2018224573A1 (en) 2018-12-13
CA3064322A1 (en) 2018-12-13
US11857616B2 (en) 2024-01-02
AU2018281889B2 (en) 2022-03-03
WO2018224573A8 (en) 2019-07-25
CN110891600A (zh) 2020-03-17
BR112019025310A2 (pt) 2020-06-23

Similar Documents

Publication Publication Date Title
JP2023107780A (ja) ジカウイルスタンパク質を発現する組換え麻疹ウイルス及びその適用
AU2013322635B2 (en) Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications
AU2018267542B2 (en) Compositions And Methods Of Vaccination Against Dengue Virus In Children And Young Adults
US9169298B2 (en) Dengue serotype 1 attenuated strain
CN116472279A (zh) 麻疹载体covid-19免疫原性组合物和疫苗
JP2010057496A (ja) キメラフラビウイルスワクチン
Tangy et al. Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector
CA3085224A1 (en) Measles-vectored lassa vaccine
EP3865180A1 (en) Live recombinant measles virus expressing coronavirus antigens - its use in eliciting immunity against coronaviruses
AU2009211379B2 (en) Flaviviridae mutants comprising a deletion in the capsid protein for use as vaccines
HK1211951B (zh) 表达屈曲病毒多肽的重组麻疹病毒及其应用
OA19870A (en) Lassa vaccine.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210607

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221011

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230518

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230607

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230630

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20250527